Search research articles
Contact Us
Filters
Showing results (161-170 of 197) with videos related to
Page
of 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Jean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Nature Communications
|
February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
Christopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2021
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer
Anna Wilkins, Elisa Fontana, Gift Nyamundanda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Barbara Burtness, Danny Rischin, Richard Greil, et al.
Cancers
|
April 3, 2021
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study
Ifigenia Vasiliadou, Omar Breik, Holly Baker, et al.
Future Oncology (London, England)
|
June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
Lisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Journal for Immunotherapy of Cancer
|
March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
The Lancet. Oncology
|
April 1, 2021
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee, Robert L Ferris, Amanda Psyrri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Kevin Harrington, Stephane Temam, Hisham Mehanna, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 197) with videos related to
Sort By:
Page
of 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Jean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Nature Communications
|
February 9, 2020
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
Christopher B Driscoll, Matthew R Schuelke, Timothy Kottke, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2021
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer
Anna Wilkins, Elisa Fontana, Gift Nyamundanda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Barbara Burtness, Danny Rischin, Richard Greil, et al.
Cancers
|
April 3, 2021
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study
Ifigenia Vasiliadou, Omar Breik, Holly Baker, et al.
Future Oncology (London, England)
|
June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
Lisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Journal for Immunotherapy of Cancer
|
March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
The Lancet. Oncology
|
April 1, 2021
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee, Robert L Ferris, Amanda Psyrri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Kevin Harrington, Stephane Temam, Hisham Mehanna, et al.
Page
of 20